B
TARA icon

Bailard’s Protara Therapeutics TARA Stock Holding History

Bailard’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,617
Closed -$97K – 850
2026
Q1 		$97K Sell
18,617
-5,800
-24% -$34.3K ﹤0.01% 727
2025
Q4 		$130K Sell
24,417
-12,252
-33% -$68.1K ﹤0.01% 731
2025
Q3 		$160K Buy
36,669
+6,900
+23% +$22.3K ﹤0.01% 745
2025
Q2 		$90.2K Hold
29,769
– – ﹤0.01% 742
2025
Q1 		$127K Hold
29,769
– – ﹤0.01% 712
2024
Q4 		$157K Buy
+29,769
New +$96.2K ﹤0.01% 704

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Bailard's TARA Position: Q2 2026 in Review

Bailard sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 18,617 shares — an estimated $97K sold.

Bailard first reported a position in TARA in Q4 2024 and held it in 6 quarters. The position peaked at $160K in Q3 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Bailard reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bailard sold 18,617 Protara Therapeutics shares in Q2 2026, an estimated $97K.
  • Bailard first reported a position in Protara Therapeutics in Q4 2024 and held it in 6 quarters.
  • Bailard's Protara Therapeutics position peaked at $160K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.